Natera agreed to acquire Foresight Diagnostics for $275 million up front plus up to $175 million in milestone payments to bring PhasED‑Seq phased‑variant MRD technology into its Signatera platform. The deal aims to improve sensitivity for ctDNA MRD detection across solid tumors and expand into lymphoma where Foresight has clinical momentum. Separately, ASH researchers presented pooled data suggesting minimal residual disease status may act as a surrogate endpoint in acute myeloid leukemia, a development that would accelerate trial timelines if regulators accept it. For context: MRD refers to sensitive assays that detect low levels of cancer DNA after treatment and can predict relapse risk.